The FDA on November 21, 2025, approved KEYTRUDA® (Pembrolizumab) or KEYTRUDA QLEX® (Pembrolizumab and Berahyaluronidase alfa-pmph) with PADCEV® (Enfortumab vedotin-ejfv) as neoadjuvant treatment followed by adjuvant treatment after cystectomy for adults with Muscle Invasive Bladder Cancer (MIBC) who are ineligible for Cisplatin. KEYTRUDA® and KEYTRUDA QLEX® are products of Merck and PADCEV® is a product of Astellas Pharma.
Bottom Ad
Advertisement
Subscribe
